跳转至内容
Merck
CN

1011007

USP

阿维A酸

United States Pharmacopeia (USP) Reference Standard

别名:

9-(4-甲氧基-2,3,6-三甲基苯基)-3,7-二甲基壬酸-2,4,6,8-四烯酸

登录 查看公司和协议定价

选择尺寸


关于此项目

经验公式(希尔记法):
C21H26O3
化学文摘社编号:
分子量:
326.43
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

等级

pharmaceutical primary standard

API类

acitretin

制造商/商品名称

USP

应用

pharmaceutical (small molecule)

包装形式

neat

SMILES字符串

COc1cc(C)c(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)c(C)c1C

InChI

1S/C21H26O3/c1-14(8-7-9-15(2)12-21(22)23)10-11-19-16(3)13-20(24-6)18(5)17(19)4/h7-13H,1-6H3,(H,22,23)/b9-7+,11-10+,14-8+,15-12+

InChI key

IHUNBGSDBOWDMA-AQFIFDHZSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Acitretin USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Acitretin Capsules

生化/生理作用

合成维甲酸,是依曲甲酸酯的代谢物。 优先与细胞视黄酸结合蛋白(CRABP) 结合。

分析说明

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他说明

Sales restrictions may apply.

警示用语:

Danger

危险分类

Aquatic Acute 1 - Aquatic Chronic 1 - Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2

储存分类代码

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology.
A D Ormerod et al.
The British journal of dermatology, 162(5), 952-963 (2010-04-29)
M Lebwohl et al.
Journal of the American Academy of Dermatology, 45(4), 544-553 (2001-09-25)
Although adjunctive treatment with retinoids in concert with either psoralen-ultraviolet A (PUVA) or ultraviolet B (UVB) phototherapy has been a treatment option for chronic, moderate to severe plaque psoriasis for nearly two decades, acitretin-UV therapy is an underutilized therapeutic modality.
Alessandro Borghi et al.
Acta dermato-venereologica, 95(3), 332-336 (2014-07-01)
The efficacy and safety of acitretin was evaluated retrospectively in a cohort of 46 patients with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index (PASI) range 10-42). Patients were treated at an initial dose of 10 mg/day acitretin
Agranulocytosis and total scalp alopecia following acitretin.
T A Chave et al.
The British journal of dermatology, 148(5), 1063-1064 (2003-06-06)
Chai Sue Lee et al.
Expert opinion on pharmacotherapy, 6(10), 1725-1734 (2005-08-10)
Acitretin is a second-generation, systemic retinoid that has been approved for the treatment of psoriasis since 1997. It can be considered one of the treatments of choice for pustular and erythrodermic psoriasis. However, the efficacy of acitretin as a monotherapy

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持